August 15, 2022

Healty Care

The Healthy Lovers

Harfst & Associates Inc. Has $1.22 Million Position in

5 min read

Harfst & Associates Inc. increased its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 6,868 shares of the company’s stock after purchasing an additional 328 shares during the quarter. Harfst & Associates Inc.’s holdings in Johnson & Johnson were worth $1,217,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Riversedge Advisors LLC lifted its holdings in shares of Johnson & Johnson by 8.6% during the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock worth $627,000 after buying an additional 289 shares during the last quarter. Hancock Whitney Corp lifted its holdings in shares of Johnson & Johnson by 0.3% during the fourth quarter. Hancock Whitney Corp now owns 65,612 shares of the company’s stock worth $11,224,000 after buying an additional 211 shares during the last quarter. PRW Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 13.7% during the fourth quarter. PRW Wealth Management LLC now owns 2,385 shares of the company’s stock worth $408,000 after buying an additional 287 shares during the last quarter. Deroy & Devereaux Private Investment Counsel Inc. lifted its holdings in shares of Johnson & Johnson by 7.2% during the fourth quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 8,926 shares of the company’s stock worth $1,527,000 after buying an additional 599 shares during the last quarter. Finally, Hamlin Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 3.5% during the fourth quarter. Hamlin Capital Management LLC now owns 518,653 shares of the company’s stock worth $88,726,000 after buying an additional 17,489 shares during the last quarter. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $172.12 on Friday. The business’s fifty day moving average price is $176.25 and its two-hundred day moving average price is $174.36. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a market capitalization of $452.92 billion, a price-to-earnings ratio of 25.05, a price-to-earnings-growth ratio of 3.48 and a beta of 0.63. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.48 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s payout ratio is presently 65.79%.

Insider Transactions at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. SVB Leerink cut their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday. Citigroup cut their target price on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday. Credit Suisse Group upped their target price on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. The Goldman Sachs Group upped their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Finally, Raymond James upped their target price on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.